Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 23, 2012

FDA Clears Eisai’s Epilepsy Drug Fycompa

  • FDA approved Eisai’s epilepsy drug Fycompa (perampanel) as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients aged 12 and over. The firm says Fycompa is the first FDA-approved non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor agonist. The drug was approved in the EU in July.

    Regulatory clearance in the U.S. was based on data from three Phase III placebo-controlled studies evaluating the efficacy and safety of perampanel when administered as an adjunctive therapy in patients aged 12 years and over with partial-onset seizures.

    FDA has recommended Fycompa is classified as a scheduled drug by the Drug Enforcement Administration, which will determine the final scheduling designation, prior to Eisai’s launch of the drug. 



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »